2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
5
Gastrointestinal
4
Thoracic
2
Genitourinary
2
Breast
2
Other solid neoplasm
1
NET
1
Head & Neck
1
Endocrine
1
Conditions
Head and Neck Neoplasms
2595
Squamous Cell Carcinoma of Head and Neck
1875
Thyroid Neoplasms
703
Nasopharyngeal Carcinoma
626
Carcinoma, Non-Small-Cell Lung
475
Mouth Neoplasms
424
Breast Neoplasms
382
Neoplasms
381
Oropharyngeal Neoplasms
359
Melanoma
339
Lung Neoplasms
317
Colorectal Neoplasms
305
Carcinoma, Squamous Cell
282
Neoplasm Metastasis
255
Laryngeal Neoplasms
253
Ovarian Neoplasms
252
Salivary Gland Neoplasms
236
Uterine Cervical Neoplasms
232
Stomach Neoplasms
223
Esophageal Neoplasms
222
Nasopharyngeal Neoplasms
220
Pancreatic Neoplasms
213
Prostatic Neoplasms
202
Carcinoma, Renal Cell
200
Thyroid Nodule
178
Thyroid Cancer, Papillary
178
Urinary Bladder Neoplasms
163
Sarcoma
160
Hypopharyngeal Neoplasms
143
Recurrence
142
Interventions
regorafenib
1
Clinical Trials, Phase II as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Tertiary Lymphoid Structures
×
Head & Neck
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled